5. Dickson BJ. Rho GTPases in growth cone guidance. Curr Opin Neurobiol 2001;11:103-10.
7. Manetti F. Recent findings confirm LIM domain kinases as emerging target candidates for cancer therapy. Curr Cancer Drug Targets 2012;12:543-60.
9. Manetti F. Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials. Eur J Med Chem 2018;155:445-58.
10. Li Y, Hu F, Chen HJ, et al. LIMK-dependent actin polymerization in primary sensory neurons promotes the development of inflammatory heat hyperalgesia in rats. Sci Signal 2014;7:ra61.
13. Maggiolini M, Recchia AG, Bonofiglio D, et al. The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor alpha in human breast cancer cells. J Mol Endocrinol 2005;35:269-81.
14. Wang G, Wang JJ, Tang XJ, et al. In vitro and in vivo evaluation of functionalized chitosan-Pluronic micelles loaded with myricetin on glioblastoma cancer. Nanomedicine 2016;12:1263-78.
15. Ko SY. Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells. Arch Oral Biol 2012;57:1623-32.
17. Wu S, Yue Y, Peng A, et al. Myricetin ameliorates brain injury and neurological deficits via Nrf2 activation after experimental stroke in middle-aged rats. Food Funct 2016;7:2624-34.
18. Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739-49.
19. Wang H, Fan X, Xie PP, et al. Deciphering the diversified metabolic behavior of hydroxyalkyl ferrocidiphenols as anticancer complexes. J Med Chem 2024;67:1209-24.
21. Katsetos CD, Herman MM, Mörk SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003;55:77-96.
24. Dolma S, Adhikari K, Mamidi T, et al. Ethamsylate attenuates mutilated secondary pathogenesis and exhibits a neuroprotective role in experimental model of spinal cord injury. Neuroscience 2022;484:26-37.
33. Yang X, He G, Zhang X, et al. Transient inhibition of LIMKs significantly attenuated central sensitization and delayed the development of chronic pain. Neuropharmacology 2017;125:284-94.
38. Gupta G, Siddiqui MA, Khan MM, et al. Current pharmacological trends on myricetin. Drug Res (Stuttg) 2020;70:448-54.
41. Huang B, Liu J, Ma D, et al. Myricetin prevents dopaminergic neurons from undergoing neuroinflammation-mediated degeneration in a lipopolysaccharide-induced Parkinson’s disease model. J Funct Foods 2018;45:452-61.
43. Dang Y, Lin G, Xie Y, et al. Quantitative determination of myricetin in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and its absolute bioavailability. Drug Res (Stuttg) 2014;64:516-22.